arrow_back Back to App

Drug Discount Access: Protecting 340B Program for Patients

This bill aims to ensure that hospitals and clinics can continue to purchase discounted drugs, regardless of where a patient picks up their medication. This will allow healthcare facilities to offer more services and medications, especially specialized ones, directly translating into better healthcare for citizens, particularly in remote areas.
Key points
Drug manufacturers cannot restrict access to discounted drugs, even if dispensed by pharmacies contracting with healthcare facilities.
The bill introduces financial penalties for manufacturers who intentionally violate drug discount program rules, protecting access to more affordable medications.
Healthcare facilities will be able to report program violations, enhancing their ability to defend patient access to drugs.
article Official text account_balance Process page
Introduced
Citizen Poll
No votes cast
Additional Information
Print number: 119_HR_4581
Sponsor: Rep. Matsui, Doris O. [D-CA-7]
Process start date: 2025-07-22
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

340B PATIENTS Act of 2025

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_HR_4581.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2025-07-22.

What are the main provisions?

Key points include:

  • Drug manufacturers cannot restrict access to discounted drugs, even if dispensed by pharmacies contracting with healthcare facilities.
  • The bill introduces financial penalties for manufacturers who intentionally violate drug discount program rules, protecting access to more affordable medications.
  • Healthcare facilities will be able to report program violations, enhancing their ability to defend patient access to drugs.
What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Matsui, Doris O. [D-CA-7].

What is the latest detailed status?

The latest detailed status is: Referred to the House Committee on Energy and Commerce.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-23.

CATEGORIES

Health